About a month after reporting it’s had a tough time starting enough patients on its treatments, bluebird bio announced it ...

Clinical trial results shared by Boehringer Ingelheim and Insilico Medicine showed improvement in idiopathic pulmonary ...

Before companies and investors look towards the future, they must first understand the opportunities and challenges AI ...

Amid a flurry of weight loss readouts, a fresh-on-the-scene startup has come out with Phase I results showing weight loss at day 36 on par with or better than competitors, with few gastrointestinal ...

In a high-profile showdown Tuesday with Sen. Bernie Sanders’ Senate health committee, Novo Nordisk CEO Lars Fruergaard ...

Flagship Pioneering–backed Generate:Biomedicines has signed its second major Big Pharma partnership, bringing in $65 million upfront to use its AI platform to discover novel protein drug candidates.

Regulators, policymakers and others can more effectively battle the disease by creating incentives to make mpox a more ...